

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10608753
	Filing Date		2003-06-27
	First Named Inventor	BOZUNG, Karl-Heinz	
	Art Unit	1614	
	Examiner Name	Webman, E.	
	Attorney Docket Number	1/1088-3-C2	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5603918		1997-02-18	McNamara, Daniel	
	2	5955058		1999-09-21	Jager, Paul D., et al	
	3	6032666		2000-03-07	Davies, Michael B., et al	
	4	6150418		2000-11-21	Hochrainer, Dieter, et al	
	5	6630466	B2	2003-10-07	Bozung, Karl-Heinz, et al	
	6	6461591	B1	2002-10-08	Keller, Manfred, et al	
	7	6481435	B2	2002-11-19	Hochrainer, Dieter, et al	
	8	6986346	B2	2006-01-17	Hochrainer, Dieter, et al	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10608753
Filing Date	2003-06-27
First Named Inventor	BOZUNG, Karl-Heinz
Art Unit	1614
Examiner Name	Webman, E.
Attorney Docket Number	1/1088-3-C2

9	7040311	B2	2006-05-09	Hochrainer, Dieter, et al	
---	---------	----	------------	---------------------------	--

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20010008632	A1	2001-07-19	Freund, Bernard, et al	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0987041	EP	A1	2000-03-22	Glaxo Wellcome Inc.		<input type="checkbox"/>
	2	2169265	GB	A	1986-07-09	Glaxo Group Ltd.		<input type="checkbox"/>
	3	00/28979	WO	A1	2000-05-25	Skyepharma AG		<input type="checkbox"/>
	4	0069468	WO	A1	2000-11-23	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>
	5	02/060532	WO	A1	2002-08-08	Boehringer Ingelheim Pharma Kg		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10608753
Filing Date		2003-06-27
First Named Inventor	BOZUNG, Karl-Heinz	
Art Unit	1614	
Examiner Name	Webman, E.	
Attorney Docket Number	1/1088-3-C2	

6	98/30262	WO	A2	1998-07-16	Glaxo Group Ltd.		<input type="checkbox"/>
7	99/18939	WO	A1	1999-04-22	Boehringer Ingelheim Pharmaceuticals, Inc.		<input type="checkbox"/>
8	99/48475	WO	A1	1999-09-30	Glaxo Group Ltd.		<input type="checkbox"/>
9	95/05805	WO	A1	1995-03-02	Astra Aktiebolag		<input type="checkbox"/>
10	00/16814	WO	A1	2000-03-30	Aeropharm Technology Inc.		<input type="checkbox"/>
11	00/07567	WO	A1	2000-02-17	Jago Research Ag		<input type="checkbox"/>
12	00/23037	WO	A1	2000-04-27	Boehringer Ingelheim Pharma Kg		<input type="checkbox"/>
13	19847970	DE	A1	2000-04-20	Boehringer Ingelhem Pharma Kg		<input type="checkbox"/>
14	87/07502	WO	A1	1987-12-17	Phares Pharmaceutical		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	---	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10608753
Filing Date	2003-06-27
First Named Inventor	BOZUNG, Karl-Heinz
Art Unit	1614
Examiner Name	Webman, E.
Attorney Docket Number	1/1088-3-C2

1	van NOORD, J.A., et al: Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium; European Respiratory Journal, Vol. 15, No. 5, May 2000, pp 878-885	<input type="checkbox"/>
2	BARNES, PETER J; Chronic obstructive pulmonary disease: new opportunities for drug development; Trends in Pharmacological Sciences, Vol. 19, No. 10, 1998, pp 415-423	<input type="checkbox"/>
3	REES, P.J.; Bronchodilators in the therapy of chronic obstructive pulmonary disease, Euro. Respir. Mon. 1998, 7, pp 135-149	<input type="checkbox"/>
4	LECKIE, MAGGIE, J.; et al; Novel Therapy for COPD, Exp. Opin. Invest. Drugs, Vol. 9, No. 1, pp3-23	<input type="checkbox"/>
5	GROSS, NICHOLAS, J., How to effectively control your patient's dyspnea, COPD Management: Achieving Bronchodilation, the Journal of Respiratory Diseases, Vol. 17, No. 3, March 1996, pp 183-195	<input type="checkbox"/>
6	HOCHRAINER, et al; Closure Cap and Container as a two chamber cartridge for nebulizers for producing aerosols and active substance formulations suitable for storage; U.S. Serial No. 09/416,476; filed 10/12/1999, Atty. Docket No. 1/1068-1070	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.